Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 13/20 | 0.37 |
| ▸ | HTR2B | P41595 | 12/20 | 0.37 |
| ▸ | HTR2A | P28223 | 11/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | KCNN3 | Q9UGI6 | 3/20 | 0.33 |
| ▸ | KCNN1 | Q92952 | 1/20 | 0.33 |
| ▸ | KCNN2 | Q9H2S1 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4956864 | 0.80 | HTR2C (0.46) | PDE10AHTR2CHTR2BHTR2A | |
| SCHEMBL4958921 | 0.80 | HTR2C (0.37) | PDE10AHTR2CHTR2BHTR2ACCNT1 | |
| SCHEMBL4955234 | 0.77 | HTR2C (0.46) | PDE10AHTR2CHTR2BHTR2A | |
| SCHEMBL4955735 | 0.75 | HTR2C (0.47) | PDE10AHTR2CHTR2BHTR2A | |
| SCHEMBL2574952 | 0.73 | HTR2C (0.63) | PDE10AHTR2CHTR2BHTR2A | |
| SCHEMBL14282916 | 0.73 | CCNE1 (0.37) | HTR2CHTR2BHTR2ACCNT1CDK9 | |
| SCHEMBL9947789 | 0.72 | HTR2C (0.65) | PDE10AHTR2CHTR2BHTR2ACCNT1 | |
| SCHEMBL4958235 | 0.69 | CYP1A2 (0.39) | HTR2CHTR2BHTR2A | |
| SCHEMBL16534726 | 0.65 | PDE10A (0.40) | PDE10ACCNT1CDK9KCNN3CHEK1 | |
| SCHEMBL7830112 | 0.65 | PDE10A (0.47) | PDE10AHTR2CKCNN3KCNN1KCNN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773345-B1 | NON-IMIDAZOLE TERTIARY AMINES AS HISTAMINE 3 RECEPTOR INHIBITORS FOR THE TREATMENT OF COGNITIVE AND SLEEP DISORDERS, OBESITY AND OTHER CNS DISORDERS | ATHERSYS INC (US) | 2013-12-11 | — | — | EP | disclosed |
| US-7319103-B2 | Non-imidazole tertiary amines as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other CNS disorders | ATHERSYS, INC. (US) | 2008-01-15 | — | — | US | disclosed |
| US-7319103-B2 | Non-imidazole tertiary amines as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other CNS disorders | ATHERSYS, INC. (US) | 2008-01-15 | — | — | US | disclosed |
| US-7319103-B2 | Non-imidazole tertiary amines as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other CNS disorders | ATHERSYS, INC. (US) | 2008-01-15 | — | — | US | disclosed |
| EP-1773345-A2 | NON-IMIDAZOLE TERTIARY AMINES AS HISTAMINE 3 RECEPTOR INHIBITORS FOR THE TREATMENT OF COGNITIVE AND SLEEP DISORDERS, OBESITY AND OTHER CNS DISORDERS | Athersys, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006004937-A2 | NON-IMIDAZOLE TERTIARY AMINES AS HISTAMINE 3 RECEPTOR INHIBITORS FOR THE TREATMENT OF COGNITIVE AND SLEEP DISORDERS, OBESITY AND OTHER CNS DISORDERS | ATHERSYS, INC. (US) | 2006-01-12 | — | — | WO | disclosed |
| US-20060009451-A1 | Non-imidazole tertiary amines as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other CNS disorders | ATHERSYS, INC. | 2006-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009451-A1 | Non-imidazole tertiary amines as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other CNS disorders | HRH3, HRH4, HRH1 | PDE10A 3468/4885HTR2C 29/4885HTR2B 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.